Comparison of 68Ga-DOTANOC PET/CT with cardiac MRI in patients with clinical suspicion of cardiac sarcoidosis

Kaushik, Prateek; Patel, Chetan; Gulati, Gurpreet Singh; Seth, Sandeep; Parakh, Neeraj; Guleria, Randeep; Kumar, Rajeev; Gupta, Priyanka; Bal, Chandrasekhar

doi:10.1007/s12149-021-01641-4

Cited by 11 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study including IPF and nonspecific interstitial pneumonia subjects, a correlative relationship between the radiotracer uptake and disease extent was only observed among the idiopathic pulmonary fibrosis subjects [ 63 ]. SSTR PET/CT is also proposed as capable of distinguishing between the acute and chronic phase in cardiac sarcoidosis, since in the chronic fibrotic stage, fibrosis is formed which is deficient in SSTR expression compared to the acute inflammatory state [ 142 ]. Patients with cardiac sarcoidosis underwent [ 68 Ga]Ga-DOTANOC cardiac PET/CT and CMR.…”

Section: Molecular Probes For Imaging Of Fibrosis and Fibrogenesismentioning

confidence: 99%

“…SSTR PET/CT is also proposed as capable of distinguishing between the acute and chronic phase in cardiac sarcoidosis, since in the chronic fibrotic stage, fibrosis is formed which is deficient in SSTR expression compared to the acute inflammatory state [142]. Patients with cardiac sarcoidosis underwent [ 68 Ga]Ga-DOTANOC cardiac PET/CT and CMR.…”

Section: Targeting Of Somatostatin Receptormentioning

confidence: 99%

“…Patients with cardiac sarcoidosis underwent [ 68 Ga]Ga-DOTANOC cardiac PET/CT and CMR. While the characteristic pattern of late gadolinium enhancement (LGE) on CMR could not specifically differentiate between inflammation and fibrosis, [ 68 Ga]Ga-DOTANOC PET/CT might be better at identifying patients with active inflammation, indicating a complementary role to CMR [142].…”

Section: Targeting Of Somatostatin Receptormentioning

confidence: 99%

See 2 more Smart Citations

Molecular Imaging of Fibrosis in Benign Diseases: An Overview of the State of the Art

Zhang,

Huang,

Jiao

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Fibrosis is a progressive pathological process participating in the progression of many diseases and can ultimately result in organ malfunction and failure. Around 45% of deaths in the United States are believed to be attributable to fibrotic disorders, and there are no favorable treatment regiments available to meet the need of blocking fibrogenesis, reversing established fibrosis, and curing diseases, especially in the terminal stage. Therefore, early detection and continuous monitoring provide valuable benefits for patients. Among all the advanced techniques developed in recent years for fibrosis evaluation, molecular imaging stands out with its distinct advantage of visualizing biochemical processes and patterns of target localization at the molecular and cellular level. In this review, we summarize the current state of the art in molecular imaging of benign fibrosis diseases. We will first introduce molecular pathways underlying fibrosis processes and potential targets. We will then elaborate on molecular probes that have been developed thus far, expounding on their mechanisms and current states of translational advancement. Finally, we will delineate the extant challenges impeding further progress in this area and the prospective benefits after overcoming these problems.

show abstract

Section: Molecular Probes For Imaging Of Fibrosis and Fibrogenesismentioning

confidence: 99%

Section: Targeting Of Somatostatin Receptormentioning

confidence: 99%

Section: Targeting Of Somatostatin Receptormentioning

confidence: 99%

See 1 more Smart Citation

Molecular Imaging of Fibrosis in Benign Diseases: An Overview of the State of the Art

Zhang,

Huang,

Jiao

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Cardiac MRI can show late gadolinium enhancement in areas not corresponding to vascular territories. This can reflect underlying scarring or ongoing nonspecific inflammation (27). Cardiac FDG-PET can similarly detect active inflammation, differentiating from scar tissue, and has a reported sensitivity of up to 89% and specificity of 78% for cardiac sarcoidosis (28).…”

Section: Differential Diagnosesmentioning

confidence: 99%